Kasaiah Makam, MD
Interventional Cardiology · Fort Dodge, IANPI 1699087395
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $2,830 of the $4,556 with a category attached, or 62.1%. 16 manufacturers reported payments, led by Medtronic at 49.5% of the total. 2025 is the largest year on record at $1,974, 2.3 times the $862 reported in 2019. That places this record below the midpoint for interventional cardiology clinicians in IA, where the typical reported total is $3,872.
Across 134 payments — averaging $34.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Johnson & Johnson$556
- ZOLL Services LLC (a/k/a ZOLL Lifecor Corp)$445
- AstraZeneca$441
- Penumbra, Inc.$297
- Edwards Lifesciences$134
- plus $428 from 10 others
What the payments were for
- Travel & lodging$1,60935%
- Food & beverage$2,83062%
- Education$1173%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 24 | $2,254 |
| Johnson & Johnson | 41 | $556 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 25 | $445 |
| AstraZeneca | 15 | $441 |
| Penumbra, Inc. | 2 | $297 |
| Edwards Lifesciences | 1 | $134 |
| Amgen | 6 | $116 |
| E.r. Squibb & Sons, L.L.C. | 5 | $72 |
| Bard Peripheral Vascular, Inc. | 3 | $67 |
| Abbott | 4 | $58 |
| Celonova Biosciences, Inc. | 1 | $37 |
| Boston Scientific | 1 | $20 |
| Cardiovascular Systems Inc. | 3 | $17 |
| Pfizer | 1 | $15 |
| Tactile Systems Technology Inc | 1 | $13 |
| Regeneron Healthcare Solutions, Inc. | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- SYMPLICITY G3$1,648
- Penumbra Ruby Coil$175
- Edwards SAPIEN 3 Transcatheter Heart Valve$134
- Ruby$122
- CoreValve Evolut$122
- BRILINTA$117
How this compares
$4,556 in reported general payments places this provider in the 50th percentile of 64 interventional cardiology providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 161 | $142,408 |
| EntrestoSacubitril/Valsartan | 41 | $30,453 |
| XareltoRivaroxaban | 24 | $29,095 |
| FarxigaDapagliflozin Propanediol | 21 | $17,480 |
| Repatha SureclickEvolocumab | 16 | $12,323 |
| Praluent PenAlirocumab | 14 | $9,449 |
| BrilintaTicagrelor | 11 | $5,484 |
| Metoprolol Succinate | 401 | $4,590 |
| Ezetimibe | 95 | $3,240 |
| Atorvastatin Calcium | 405 | $2,787 |
| Enoxaparin Sodium | 19 | $1,583 |
| Ranolazine ErRanolazine | 11 | $1,274 |
| Rosuvastatin Calcium | 103 | $1,273 |
| Amlodipine Besylate | 252 | $1,192 |
| ClopidogrelClopidogrel Bisulfate | 109 | $807 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $15 | $142,408161 claims |
| Johnson & JohnsonXarelto | $556 | $29,09524 claims |
| AstraZenecaFarxiga, Brilinta | $441 | $22,96332 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 50th percentile of 64 interventional cardiology providers in Iowa.
Other interventional cardiology in Fort Dodge
- Joseph CookmanFort Dodge$1K
- John Michael Chua ChiacoFort Dodge$241
- Nicolas ShammasDavenport$808K
- Eric DippelDavenport$100K
- Atul ChawlaDes Moines$78K
- Magdi GhaliWest Des Moines$64K
- David McAllisterDes Moines$55K
- Daniel ShivapourDes Moines$54K
- Srikanth KasulaDavenport$43K
- Abdulrahman AbdulbakiDes Moines$43K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.